Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Neratinib, Endocrine Therapy, and Trastuzumab in ER+/HER2+ Breast Cancer
NCT04886531Phase 2Recruiting
- Sponsor
- Ruth O'Regan
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Ruth O'Regan. Started Jul 2022; status: recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04886531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886531.